Akebia Therapeutics (AKBA) Invested Capital (2016 - 2025)
Akebia Therapeutics (AKBA) has disclosed Invested Capital for 9 consecutive years, with $80.9 million as the latest value for Q4 2025.
- On a quarterly basis, Invested Capital rose 870.68% to $80.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $80.9 million, a 870.68% increase, with the full-year FY2025 number at $80.9 million, up 870.68% from a year prior.
- Invested Capital was $80.9 million for Q4 2025 at Akebia Therapeutics, down from $89.2 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $213.9 million in Q1 2021 to a low of -$31.4 million in Q3 2023.
- A 5-year average of $69.9 million and a median of $72.8 million in 2022 define the central range for Invested Capital.
- Peak YoY movement for Invested Capital: crashed 355.96% in 2024, then skyrocketed 2362.49% in 2025.
- Akebia Therapeutics' Invested Capital stood at $171.6 million in 2021, then plummeted by 58.43% to $71.3 million in 2022, then plummeted by 94.25% to $4.1 million in 2023, then crashed by 355.96% to -$10.5 million in 2024, then surged by 870.68% to $80.9 million in 2025.
- Per Business Quant, the three most recent readings for AKBA's Invested Capital are $80.9 million (Q4 2025), $89.2 million (Q3 2025), and $76.3 million (Q2 2025).